Decoding the Oncogenic Role of USP22 Through Pan‐Cancer Genomic and Epigenetic Analysis
Cancer Reports · 2026-05 · 9 (5)
DOI: 10.1002/cnr2.70572 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, online erschienen am 13.05.2026. Verfasst von Uma Devi A und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Bioseparation Technology, VIT, Vellore, India. Hauptthemen laut MEDLINE: Ubiquitin Thiolesterase, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: VIT University, Department of Biotechnology, India.
Abstract (Originalsprache)
Background
Ubiquitin‐specific protease 22, an important catalytic component of the human SAGA (Spt‐Ada‐GcN5 Acetyltransferase) complex, regulates the deubiquitination and methylation of histones, which in turn influences gene expression. Its overexpression alters gene regulation, transcription, cancer progression, and therapy resistance. Its role is increasingly being noticed in cancers.
Aims
To conducted a pan‐cancer analysis across multiple malignancies, as it allows for a comprehensive assessment of USP22 expression, regulation, and clinical impact.
Methods
The Human Protein Atlas, UALCAN, and Timer 2.0 were used to examine USP22 expression at the gene and protein levels in 33 TCGA cancer types. Furthermore, various tools have been employed to study genetic changes, overall survival (OS), disease‐free survival (DFS), DNA methylation profiles, and immune associations. Gene correlation and protein–protein interaction were examined.
Results
USP22 expression level was observed to be significantly higher in 13 distinct cancer types among the 33 TCGA cancer types. Along with the pathological stages of the TCGA sample, it showed overexpression in the histological subtypes, TP53 mutant stages, and tumor grade in numerous cancers compared to the control. According to the study, elevated USP22 expression was linked to a worse chance of survival and a lower OS rate in several types of cancer. High expression of USP22 is linked to a poor immunosuppressive microenvironment, and the CpG‐aggregated methylation analysis shows that the gene is significantly hypomethylated in tumor samples, which is highly associated with its known upregulation in cancer.
Conclusion
USP22 may have potential relevance in cancer, and the pathways associated with it could offer possible targets for therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Bioseparation Technology, VIT, Vellore, India.
ORCID-Profile: Prakash Kumar Shukla
Förderung
- VIT University
- Department of Biotechnology, India
Zitieren
APA
A, U. D., & Shukla, P. K. (2026). Decoding the Oncogenic Role of USP22 Through Pan‐Cancer Genomic and Epigenetic Analysis. Cancer Reports, 9(5). https://doi.org/10.1002/cnr2.70572
Vancouver
A UD, Shukla PK. Decoding the Oncogenic Role of USP22 Through Pan‐Cancer Genomic and Epigenetic Analysis. Cancer Reports. 2026;9(5). doi:10.1002/cnr2.70572
BibTeX
@article{A2026,
author = {A, Uma Devi and Shukla, Prakash Kumar},
title = {Decoding the Oncogenic Role of USP22 Through Pan‐Cancer Genomic and Epigenetic Analysis},
journal = {Cancer Reports},
year = {2026},
volume = {9},
number = {5},
doi = {10.1002/cnr2.70572}
}
EUVIMED